The Battle Over BRCA1 Goes to Court; BRCA2 May Be Next

See allHide authors and affiliations

Science  12 Dec 1997:
Vol. 278, Issue 5345, pp. 1874
DOI: 10.1126/science.278.5345.1874

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


What began a decade ago as a race to find the genes that increase a woman's risk for breast cancer (BRCA1 and BRCA2) has evolved into a bitter court battle over who owns the right to exploit these genes commercially. Over the past month, two U.S. genetic testing companies have sued each other for patent violations. The legal jousting once again raises questions about the value of gene patents and threatens to stir up old grievances in the field.